Loading
Of the fifteen drugs whose Medicare-negotiated prices start on 1 January 2027, four are cancer medicines: Xtandi (enzalutamide), Pomalyst (pomalidomide), Ibrance (palbociclib) and Calquence (acalabrutinib).
United States, Medicare Drug Price Negotiation Program, second cycle. CMS's data file of 2 November 2026 lists fifteen selected drugs for initial price applicability year 2027, with maximum fair prices effective 1 January 2027. The four cancer medicines and their single maximum fair price per 30-day equivalent supply, as the file gives them:
- Xtandi (enzalutamide): $7,004.00 - Pomalyst (pomalidomide): $8,650.00 - Ibrance (palbociclib): $7,871.00 - Calquence (acalabrutinib): $8,600.00
Showing the molecule this term concerns: Enzalutamide.
Shares Inflation Reduction Act 2022: Medicare drug price negotiation, Prices and value and the tags law, us.
Shares Inflation Reduction Act 2022: Medicare drug price negotiation, Prices and value and the tags law, us.
Shares Inflation Reduction Act 2022: Medicare drug price negotiation, Prices and value and the tags law, us.
Shares Inflation Reduction Act 2022: Medicare drug price negotiation, Prices and value and the tags law, us.
Shares Inflation Reduction Act 2022: Medicare drug price negotiation, Prices and value and the tags law, us.
Shares the tags law, us.
Shares the tags law, us.
Shares the tags law, us.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/